TerminatedInterventionalPhase 3Last updated Nov 30, 2021

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma

Overview

ClinicalTrials.gov ID: NCT01387932
Lead Sponsor: Merit Medical Systems, Inc.INDUSTRY
Brief Summary: The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to conventional transarterial chemoembolization with particle PVA, lipiodol, and doxorubicin.
Study Type

Status

Overall Status: Terminated
Start Date: Jun 2011Actual
Primary Completion Date: Feb 2021Actual
Completion Date: Feb 2021Actual

Study Record Dates

First Submitted: Apr 11, 2011
First Submitted that Met QC Criteria: Jul 5, 2011
First Posted: Jul 6, 2011Estimated
Last Update Submitted that Met QC Criteria: Nov 2, 2021
Last Update Posted: Nov 30, 2021Actual
Last Verified: Nov 2021

NCT00936689Completed

Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE

NCT01116635Completed

Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)

NCT01891539Unknown status

Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma

NCT02141906Completed

A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin

NCT03264716Completed

Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis

NCT05911633Recruiting

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)